Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion

Molecular Cancer Research

Volumn 6, Issue 4, 2008, Pages 525-534

  Belotti, Dorina ^a   Calcagno, Catia ^a   Garofalo, Angela ^a   Caronia, Daniela ^a   Riccardi, Elena ^a   Giavazzi, Raffaella ^a   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COMPLEMENTARY DNA; GELATINASE; GELATINASE B; VASCULOTROPIN; VASCULOTROPIN 121;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR GROWTH; ZYMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; OVARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS; MUS MUSCULUS;

EID: 42049094423     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0366     Document Type: Article

References (44)

1. Kohn EC. Angiogenesis in ovarian carcinoma: a formidable biomarker. Cancer 1997;80:2219-21.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
3. Davidson B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets 2007;7:109-20.
4. Cormio G, Maneo A, Parma G, Pittelli MR, Miceli MD, Bonazzi C. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Ann Oncol 1995;6:571-4.
5. Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7.
6. Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001;81:398-403.
7. Kaplan RN, Rafii SLyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93.
8. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
9. Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res 2006;66:259-66.
10. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinase 2 & 9 and tissue inhibitor of metalloproteinases 1 & 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39:1948-56.
11. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
12. Manenti L, Riccardi E, Marchini S, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 2005;4:715-25.
13. Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003;9:3476-85.
14. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007;5:1015-30.
15. Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003;10:89-95.
16. Zhang A, Meng L, Wang Q, et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 2006;15:831-6.
17. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42.
18. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91.
19. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-91.
20. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa α2- microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386-8.
21. Folkesson M, Kazi M, Zhu C, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 2007;98:427-33.
22. Schumacher JJ, Dings RP, Cosin J, Subramanian IV, Auersperg N, Ramakrishnan S. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res 2007;67:3683-90.
23. Guo P, Xu L, Pan S, et al. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 2001;61:8569-77.
24. Springer ML, Banfi A, Ye J, et al. Localization of vascular response to VEGF is not dependent on heparin binding. FASEB J 2007;21:2074-85.
25. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006;118:879-88.
26. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-305.
27. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006;103:12493-8.
28. Ribeiro LA, Turba ME, Zannoni A, Bacci ML, Forni M. Gelatinases, endonuclease and vascular endothelial growth factor during development and regression of swine luteal tissue. BMC Dev Biol 2006;6:58.
29. Otani N, Minami S, Yamoto M, et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999;84:3845-51.
30. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161:1917-24.
31. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6.
32. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8.
33. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4:985-92.
34. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53:2087-91.
35. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
36. Bani MR, Nicoletti MI, Alkharouf NW, et al. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004;3:111-21.
37. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
38. Ribatti D, Gualandris A, Belleri M, et al. Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. J Pathol 1999;189:590-9.
39. Dong QG, Bernasconi S, Lostaglio S, et al. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 1997;17:1599-604.
40. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
41. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61.
42. Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006;345:438-45.
43. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
44. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.